MAPT and Alzheimer disease: Previous studies have showed that the glutamine levels are lower in the brains of patients with Alzheimer's disease (AD), and the glutamine supplementation could reduce inflammation-induced neuronal cell cycle activation, tau phosphorylation, and ATM-activation in a mouse model of AD [10].